Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients

by Boyle, H., Négrier, S.
Published 2011

Pretreatment serum CRP and response to interleukin 2.

by Blay, J. Y., Négrier, S., Philip, T., Favrot, M., Mercatello, A.
Published 1994

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α

by Patil, S, Figlin, R A, Hutson, T E, Michaelson, M D, Negrier, S, Kim, S T, Huang, X, Motzer, R J
Published 2012

Alpha Cyano-4-Hydroxy-3-Methoxycinnamic Acid Inhibits Proliferation and Induces Apoptosis in Human Breast Cancer Cells

by Hamdan, Lamia, Arrar, Zoheir, Al Muataz, Yacoub, Suleiman, Lutfi, Négrier, Claude, Mulengi, Joseph Kajima, Boukerche, Habib
Published 2013

Interpreting overall survival results when progression-free survival benefits exist in today’s oncology landscape: a metastatic renal cell carcinoma case study

by Tang, Yiyun, Bycott, Paul, Åkerborg, Örjan, Jönsson, Linus, Negrier, Sylvie, Chen, Connie
Published 2014

Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.

by Philip, T., Negrier, S., Lasset, C., Coronel, B., Bret, M., Blay, J. Y., Merrouche, Y., Carrie, C., Kaemmerlen, P., Chauvin, F.
Published 1993

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.

by Ravaud, A., Négrier, S., Cany, L., Merrouche, Y., Le Guillou, M., Blay, J. Y., Clavel, M., Gaston, R., Oskam, R., Philip, T.
Published 1994

A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal

by Kerebel, Delphine, Joly, Luc-Marie, Honnart, Didier, Schmidt, Jeannot, Galanaud, Damien, Negrier, Claude, Kursten, Friedrich, Coriat, Pierre
Published 2013

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma

by Jobard, Elodie, Blanc, Ellen, Négrier, Sylvie, Escudier, Bernard, Gravis, Gwenaelle, Chevreau, Christine, Elena-Herrmann, Bénédicte, Trédan, Olivier
Published 2015

Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate)

by Negrier, Claude, Voisin, Sophie, Baghaei, Fariba, Numerof, Robert, Novack, Aaron, Doralt, Jennifer E., Romanov, Vadim, Gringeri, Alessandro
Published 2016

Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.

by Négrier, S., Mercatello, A., Bret, M., Thiesse, P., Blay, J. Y., Coronel, B., Merrouche, Y., Oskam, R., Franks, C. R., Clavel, M.
Published 1992

Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.

by Bain, C., Merrouche, Y., Puisieux, I., Blay, J. Y., Negrier, S., Bonadona, V., Lasset, C., Lanier, F., Duc, A., Gebuhrer, L., Philip, T., Favrot, M. C.
Published 1997

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors

by Sylvie Négrier, David Pérol, Rastislav Bahleda, Antoine Hollebecque, Etienne Chatelut, Helen Boyle, Philippe Cassier, Séverine Metzger, Ellen Blanc, Jean-Charles Soria, Bernard Escudier
Published 2017-08-01

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

by Eisen, T, Marais, R, Affolter, A, Lorigan, P, Robert, C, Corrie, P, Ottensmeier, C, Chevreau, C, Chao, D, Nathan, P D, Jouary, T, Harries, M, Negrier, S, Montegriffo, E, Ahmad, T, Gibbens, I, James, M G, Strauss, U P, Prendergast, S, Gore, M E
Published 2011

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma

by Harmon, Charles S., DePrimo, Samuel E., Figlin, Robert A., Hudes, Gary R., Hutson, Thomas E., Michaelson, M. Dror, Négrier, Sylvie, Kim, Sindy T., Huang, Xin, Williams, J. Andrew, Eisen, Tim, Motzer, Robert J.
Published 2013

Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma

by Cella, David, Davis, Mellar P, Négrier, Sylvie, Figlin, Robert A, Michaelson, M Dror, Bushmakin, Andrew G, Cappelleri, Joseph C, Sandin, Rickard, Korytowsky, Beata, Charbonneau, Claudie, Matczak, Ewa, Motzer, Robert J
Published 2014

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib

by Beuselinck, B, Karadimou, A, Lambrechts, D, Claes, B, Wolter, P, Couchy, G, Berkers, J, Paridaens, R, Schöffski, P, Méjean, A, Verkarre, V, Lerut, E, de la Taille, A, Tourani, J-M, Bigot, P, Linassier, C, Négrier, S, Berger, J, Patard, J-J, Zucman-Rossi, J, Oudard, S
Published 2013